Skip to main content
Clinical Trials/NCT03995524
NCT03995524
Completed
Not Applicable

Perceived Spasticity and Treatment Satisfaction Among Stroke Survivors Over the Course of a Complete Treatment Cycle With Botulinum Neurotoxin A (BoNT-A): an Ethnographic Study.

Ipsen1 site in 1 country30 target enrollmentJuly 20, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Spasticity as Sequela of Stroke
Sponsor
Ipsen
Enrollment
30
Locations
1
Primary Endpoint
Severity of Pain
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

To investigate, through ethnography, changes in symptom burden and disability and their effects/interference on patient functioning, ability to perform activities of daily living (ADL) and quality of life (QoL) throughout the duration of one BoNT-A treatment cycle.

Registry
clinicaltrials.gov
Start Date
July 20, 2019
End Date
May 12, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Ipsen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnostic of post-stroke spasticity more than three months prior to inclusion
  • At least 6 months on treatment (or two treatment cycles) with BoNT-A injections for spasticity according to the decision of the physician
  • Previous BoNT-A injection cycles did not last for more than 16 weeks
  • Ambulatory (use of walking aids is acceptable)

Exclusion Criteria

  • Neurological disorder other than stroke
  • Spasticity-specific treatment changes within 3 months prior to inclusion
  • Patients who had undergone neurolysis or surgery to the affected limb within 6 months
  • Concurrent participation in a clinical trial for the treatment of spasticity

Outcomes

Primary Outcomes

Severity of Pain

Time Frame: 12 weeks

Severity of Pain as per EQ-5D-5L and a sliding scale. This is a descriptive scale that covers 5 dimensions: mobility, self-care, usual activities,pain/discomfort and anxiety/depression. the scale consist of 5 levels, where level one corresponds to "no problems" and level 5 corresponds to "extreme problem".

Degree of functional limitations in daily life activities

Time Frame: monthly for 12 Weeks, or until end of injection cycle whichever occurs first

Degree of functional limitations in daily life activities (i.e. physical functioning) associated with post-stroke spasticity as assessed by using WHODAS parameters, and identification of their characteristics and changes over time

Health status in subjects with post-stroke spasticity

Time Frame: weekly for 12 Weeks, or until end of injection cycle whichever occurs first

Health status in subjects with post-stroke spasticity as assessed by using EQ-5D-5L parameters, and identification of their characteristics and changes over time

Secondary Outcomes

  • Burden of spasticity/treatment(Opening interview and ending qualitative interviews, ethnography data which will be provided at discretion of patient/caregiver for 12 weeks or duration of treatment, whichever occurs first, may also support these qualitative analyses)
  • Comparison of feedback between caregivers and stroke survivors(opening ( before week 1) and ending ( 2 weeks after end of injection cycle) qualitative interviews)
  • Patients' satisfaction(weekly for 12 weeks or until end of injection cycle whichever occurs first. Opening and closing interview will also explore this)

Study Sites (1)

Loading locations...

Similar Trials